World Journal of
Pharmaceutical and Life Sciences

RECENT ADVANCES IN STUDY OF EXPERIMENTAL MODELS AVAILABLE FOR PHARMACOLOGICAL SCREENING OF ANTIDIABETICS

Rama Chandra Rout*, Prasanna Kumar Panda, Lelin Behera and Santosh Kumar Panda

ABSTRACT

Diabetes is a chronic disease. It might be a global morbidity. As a result, this condition poses a significant health risk. The quest for chemicals with the best qualities for treating illnesses is continuously ongoing. Experimental models are used in it. The goal of this study is to put all of the reported models together, highlighting their benefits and drawbacks, as well as the precautions that each model or approach requires. Diabetes comes in two forms. Type-I diabetes necessitated the use of insulin, but type-II diabetes can be managed in a variety of ways. Diabetes is caused by hyperglycemia, which is a leading cause of the disease. Hyperglycemia has a part in the development of diabetes as well. A rise in blood sugar level has a negative impact on the important organs. Diabetes impairs the function of the heart, kidneys, and eyes. This review article aims to bring together various animal models for antidiabetic activity screening, such as alloxan-induced and streptozotacin-induced diabetes in rats, as well as alternative animal models for antidiabetic activity screening, such as in vitro alpha amylase inhibiting assays, glucosidase inhibitory activity etc. as well as their benefits and drawbacks.

[Full Text Article]   [Download Certificate]